T1	p 61 103	patients with alcoholic liver disease -- a
T2	p 312 325	liver disease
T3	p 438 571	patients with alcoholic liver disease . Fifty patients with alcoholic liver disease ( 27 with cirrhosis , 23 without cirrhosis ) were
T4	p 896 917	15 healthy controls .
T5	p 1688 1727	patients with alcoholic liver disease .
T6	i 26 42	with paromomycin
T7	i 119 137	placebo-controlled
T8	i 223 245	gut-derived endotoxins
T9	i 378 419	nonabsorbable , broad-spectrum antibiotic
T10	i 601 654	either paromomycin sulfate ( 3 x 1 g/day ) or placebo
T11	i 730 739	Endotoxin
T12	i 935 957	paromomycin or placebo
T13	i 1318 1329	paromomycin
T14	i 1352 1359	placebo
T15	i 1396 1407	paromomycin
T16	i 1547 1558	paromomycin
T17	o 740 810	concentration , liver function tests , and other laboratory parameters
T18	o 849 872	Endotoxin concentration
T19	o 1032 1064	initial endotoxin concentrations
T20	o 1245 1273	mean endotoxin concentration
T21	o 1447 1494	endotoxin concentration or liver function tests
T22	o 1526 1543	beneficial effect
T23	o 1572 1583	endotoxemia
T24	o 1587 1597	cirrhotics